Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Source filing unavailable
| Metric | Q4 2021 | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.59M | $4.23M | — | — |
| Net Income | -$25.93M | -$17.72M | -$16.12M | -$8.86M |
| EPS Diluted | -$0.64 | — |
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
| — |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
